ClinicalTrials.gg
RecruitingNCT07291180Updated Jul 21, 2026

A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis

An interventional study of Mass-based response testing (MRT) in Appendiceal Cancer, Colorectal Adenocarcinoma and Peritoneal Metastases, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 81 Years. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Yale University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 81 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in Appendiceal Neoplasms with a site in United States — 19 open to participants now, 24 under way, 1 of them phase 3. Appendiceal Neoplasms · United States.

Planned enrollment
41st of 52
20 · median 42
Started
2026
with 5 others
No phase
13 of 66
6 open now
Primary completion
2027-10
later than 9 of 23 live
Registered
63rd of 66
by date

Among the 66 studies in Appendiceal Neoplasms with a site in United States, this one is the 41st largest by planned enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2026, is one of 13 with no phase, reaches primary completion later than 9 of the 23 other live ones, and was the 63rd registered.

Appendiceal Neoplasms

86 studies on the registry are indexed under Appendiceal Neoplasms; 25 are open to participants now.

Browse Appendiceal Neoplasms studies →

Open to participants now

19 of the 66 studies in Appendiceal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Appendiceal Neoplasms studies recruiting now, 17 (71%) set no upper age limit and 4 (17%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 81 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Appendiceal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the role of mass-based response testing (MRT) to select and deliver personalized hyperthermic intraperitoneal chemotherapy (HIPEC) regimens to patients with peritoneal metastasis (PM) from high-grade appendiceal adenocarcinomas (HGAA) and colorectal cancer (CRC).

Read the detailed description

Patients with peritoneal metastases from colorectal and appendix cancer are treated with cytoreductive surgery and HIPEC. However, several patients are considered unresectable due to the inability to remove all the cancer safely. Repeated (Iterative) intra-peritoneal chemotherapy delivered via HIPEC laparoscopically has been shown to have favorable outcomes with a potential increase in sensitivity to immunotherapy . Such procedures often use chemotherapy that is not tailored to the patients cancer.

In this study, patients with unresectable colorectal and appendiceal peritoneal metastases will undergo MRT on tissue biopsies to determine optimal chemotherapy regimen to be delivered intraperitoneally. For patients with unresectable disease, iterative HIPEC (IHIPEC) will be administered starting three weeks after the laparoscopy. (IHIPEC refers to HIPEC followed by systemic chemotherapy repeated 3 times with approximately 6 weeks in between each HIPEC.)

03

Conditions studied

  • Appendiceal Cancer
  • Colorectal Adenocarcinoma
  • Peritoneal Metastases

Browse trials for

Keywords

  • Appendiceal Cancer
  • Colorectal Adenocarcinoma
  • Peritoneal Metastases
  • Iterative Hyperthermic Intraperitoneal Chemotherapy (IHIPEC)
04

Who can participate

Ages eligible
18 Years to 81 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has confirmed peritoneal with primary diagnosis of AJCC 8th Edition Stage IV

    1. Appendiceal adenocarcinoma (moderately/poorly differentiated, and/or signet ring cell tumors)
    2. Colorectal adenocarcinoma
    3. Suspected colon, small bowel, or appendiceal adenocarcinoma in setting of unknown primary
  • Limited or no extraperitoneal metastases (any of the below)

    a) Any extraperitoneal metastases must be limited, stable and treatable

  • Has adequate organ function, as described below; all screening laboratory tests should be performed within 30 days prior to the first HIPEC
  • Expected survival at the time of first HIPEC is greater than 3 months
  • Exhibits unresectable disease (bowel or mesenteric involvement) or PCI > 19

Demographics

  • Adult patient at least 18 years of age at the time of signing and less than 81 years of age at the time of signing informed consent.
  • Has an performance status score of 0-2.

Male Participants

  • A male participant must agree to use (barrier birth control, abstinence) during the treatment period and for at least 95 days following completion, corresponding to time needed to eliminate any study intervention(s), and refrain from donating sperm during this period.

Female Participants

  • A female participant of childbearing age is eligible to participate if she is not pregnant, not breastfeeding, and agrees to use contraception (hormonal, barrier birth control, or abstinence). Should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately.

Informed Consent

  • The participant (or legally acceptable representative if applicable) provides written informed consent for the study. The participant may also provide consent for FBR. However, the participant may participate in the main study without participating in FBR.

Alternative Eligibility

  • In addition to the criteria above, if a patient has undergone less than 8 rounds of chemotherapy at another institution (prior to initial diagnostic laparoscopy) and has not undergone radiation, ablative procedures, or cytoreductive surgery, then they are still eligible to enter the study at the second diagnostic laparoscopy step

Exclusion criteria

Exclusion Criteria:

  • Has a positive urine pregnancy test within 3 days prior to randomization or treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  • Has a known allergy to medications used in this study. Note: In the event that 3 days have elapsed between the screening pregnancy test and the first dose of study intervention, another pregnancy test (urine or serum) must be performed and must be negative for the participant to start receiving study medication.
  • Has hypoxia as defined by pulse oximeter reading \<92% at rest or requires intermittent or chronic supplemental oxygen.
  • No concurrent that may interfere with the study aims at the discretion of the investigator.

Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.

  • Has known significant extraperitoneal .
  • Has creatine clearance \<60 mL/m\^2 per the formula
  • Has cardiac disease, including unstable angina, acute myocardial infarction within 6 months from treatment initiation, or Class III or IV congestive heart failure. Medially controlled arrhythmia stable on medication is permitted.
  • Has poorly controlled hypertension defined as SBP ≥150mmHg and/or DBP ≥90mmHg.
  • Has moderate to severe hepatic impairment ( B or C).
  • Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.
  • Is unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (severe dysphasia, bowel obstruction, malabsorption).
  • Has progressive disease following the first 3 months of systemic chemotherapy prior to HIPEC who is not in a stable condition to continue with the trial.

Prior/Concomitant Therapy

  • Has received radiation, ablative procedures, cytoreductive surgery, or systemic therapy including chemotherapy to treat metastatic disease within 3 months of initial laparoscopy.

Diagnostic Assessments

  • Has an active infection requiring systemic therapy.
  • Has a known active TB/ COVID infection.
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (dosing exceeding 10mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of the study intervention.
  • Has a known history of poorly controlled infection despite anti-retroviral therapy.
  • Has a known history of (defined as HBsAg reactive) or known active (defined as HCV RNA [qualitative] is detected) infection that is poorly controlled.

Note: Testing for HBV and HCV is only required if mandated by the local health authority.

Other Exclusions

  • Inability to receive chemotherapy due to medical/insurance reasons.
  • Requires emergency surgery due to bleeding, perforation, or obstruction.
  • Has undergone previous iterative intraperitoneal therapy.
  • Has to chemotherapy of choice.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    MRT

    Participants with high-grade appendiceal and colorectal peritoneal metastasis will receive MRT to select and deliver personalized HIPEC regimens to participants undergoing IHIPEC

    Device: Mass-based response testing (MRT)

Interventions

  • DeviceMass-based response testing (MRT)

    Travera has developed a clinical workflow that combines single-cell mass measurements with inline brightfield imaging and machine-learning based image classification to perform mass-based response testing (MRT) directly on live tumor cells collected from patients. MRT enables tumor cells across a wide range tissue sample formats to be dosed with a panel of drugs in vitro, agnostic to malignancy or drug mechanism.

06

What researchers measure

Primary outcomes

  1. Feasibility of performing MRT to select and deliver personalized HIPEC

    Feasibility is defined as the percentage of treatment naïve and pretreated patients who successfully receive drug screening results within one week of tissue sampling from at least one peritoneal biopsy. This means that the test has enough tumor cell viability and purity to come back with specific results indicating sensitivities of HIPEC drugs and does not give an inconclusive result (due to insufficient tissue sample).

    Time frame: at end of study, up to 12 months

Secondary outcomes

  1. Concordance of MRT Results

    Defined as the percentage of patients who receive identical HIPEC recommendations (reflecting the best response to MRT) in both rounds of testing. Concordance will only be evaluated for the subset of patients who have received two biopsies and Travera screenings.

    Time frame: at end of study, up to 12 months

  2. One Year Overall Survival (OS)

    Overall survival of patients will be measured from two time points: From the diagnosis of peritoneal metastasis to death from any cause at the end of follow-up (1 year). From the first HIPEC procedure to death from any cause at the end of follow-up (1 year).

    Time frame: up to 12 months

  3. Percentage of participants with Perioperative and Postoperative Complications

    Percentage of participants that experienced any perioperative or postoperative complications will be graded using the CTCAE version 5. Complications will be noted during hospitalization or within 30 days of each HIPEC procedure, and incidence will be measured separately for patients undergoing IHIPEC.

    Time frame: up to 12 months

  4. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) mean score

    A tool used to assess the quality of life in cancer patients. It contains 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial impact) 10. It is scored on a 4-point scale (1 = not at all, 2 = a little, 3 = quite a bit, 4 = very much). The EORTC QLQ-C30 instrument also contains 1 global health status/QoL scale that uses a 7-point scale scoring with anchors (1 = very poor and 7 = excellent).

    Time frame: every 3 months post last IHIPEC, up to 12 months

  5. Change in Comprehensive Score for Financial Toxicity (COST)

    The COST is a standardized instrument for use as a measure of financial toxicity. The COST questionnaire is a patient-friendly tool that has demonstrated reliability, validity, and internal consistency. It has demonstrated an association with health-related quality of life (HRQOL). It contains 12 brief statements about the financial burden, cost, resources, and concerns related to them. It is scored by the patients on a 5-point scale (0=not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4=very much). A composite score is then calculated, with a lower score indicating financial toxicity.

    Time frame: every 3 months post last IHIPEC, up to 12 months

  6. Change in Peritoneal Regression Grading Score (PRGS)

    PRGS is a scoring system used to assess tumor regression in biopsies from patients with peritoneal metastasis undergoing therapy. Peritoneal punch biopsies will be collected from all four abdominal quadrants at the start of each IHIPEC procedure. The attending pathologist will evaluate each biopsy and assign a grade, ranging from 1 (indicating a complete response) to 4 (indicating no response). These individual scores will then be averaged to calculate the overall PRGS score. The change in PRGS is defined as the difference in PRGS between the first and last IHIPEC procedure that a patient receives.

    Time frame: at first IHIPEC post biopsy to last IHIPEC received, up to 12 months

  7. Change in Peritoneal Cancer Index (PCI) Score

    The change in PCI score will only be measured for patients undergoing IHIPEC. The PCI is a scoring system used to quantify the extent of peritoneal carcinomatosis. The abdomen is divided into 13 regions and assigned a score ranging from 0 to 3 based on presence and size of peritoneal tumor implants in each region. This score can range from 0 (no evidence of disease) to 39 (extensive disease). PCI scores will be assessed and recorded by the attending physician following peritoneal cavity exploration before each IHIPEC procedure. The change in PCI score is defined as the difference in PCI between the first and last IHIPEC procedure that a patient receives.

    Time frame: during each diagnostic laparoscopy at approximately month 1 and month 6

  8. Complete Cytoreduction Rate

    The complete cytoreduction rate will only be measured for patients undergoing IHIPEC. This rate is defined by the percentage of patients who receive a CC0 (indicates no residual tumor visible to the naked eye) or CC1 (indicates minimal residual tumor visible) after completing the IHIPEC protocol. This metric assesses the ability of MRT-selected personalized IHIPEC to downstage PM tumor burden and improve the rate of resection.

    Time frame: during each IHIPEC cycle, up to 12 months

  9. Mean MRT Turnaround Time

    The mean time in days that it takes for MRT personalized drug readouts to come back to the medical team will be recorded: from the time the biopsy is shipped to Travera to the time the personalized drug readouts are made accessible to the medical team.

    Time frame: up to 12 months

  10. MRT Success Rate

    The percentage of MRT results that come back with specific personalized drug readouts will be recorded. This excludes MRT results that were inconclusive or had an inadequate cancer cell sample or insufficient tumor cell purity to conduct MRT.

    Time frame: up to 12 months

  11. MRT Tumor Cell Viability

    The percentage of MRT results that come back as inconclusive due to inadequate tumor cell viability will be recorded. Cell viability can be defined as the percentage of tumor cells that have sufficient metabolic activity to undergo accurate MRT testing as to not receive an inconclusive result.

    Time frame: up to 12 months

  12. MRT Tumor Cell Purity:

    The percentage of MRT results that come back as inconclusive due to inadequate tumor cell purity will be recorded. Tumor cell purity can be defined as the percentage of biopsies submitted for MRT with a sufficient proportion of malignant cancer cells in the tumor mass as to not receive an inconclusive result.

    Time frame: up to 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Oct 2027, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2025
First posted
Dec 18, 2025
StartActual
Feb 17, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Dec 2027
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07291180
Lead sponsor
Yale University
Collaborators
Travera Inc
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Feb 17, 2026
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 21, 2026

Study contacts

Wumi Jemiseye, MPH
Contact
wumi.jemiseye@yale.edu
203-737-4475
Rodolfo N Molina, MD
Contact
Rodolfo.molina@yale.edu
203-737-4475
Kiran Turaga, MD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion